Current Report Filing (8-k)
August 20 2021 - 12:15PM
Edgar (US Regulatory)
0000830656
false
0000830656
2021-08-18
2021-08-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant
to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported) August 18, 2021
PRESSURE
BIOSCIENCES, INC.
|
(Exact
Name of Registrant as Specified in its Charter)
|
massachusetts
|
(State
or Other Jurisdiction of Incorporation)
|
001-38185
|
|
04-2652826
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
14
Norfolk Avenue, South Easton, MA
|
|
02375
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(508)
230-1828
|
(Registrant’s
Telephone Number, Including Area Code)
|
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
None
|
|
None
|
|
None
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Cautionary
Note Regarding Forward-Looking Statements
This
Current Report on Form 8-K includes information that may constitute forward-looking statements. These forward-looking statements are
based on the Company’s current beliefs, assumptions and expectations regarding future events, which in turn are based on information
currently available to the Company. By their nature, forward-looking statements address matters that are subject to risks and uncertainties.
Forward looking statements include, without limitation, statements relating to projected industry growth rates, the Company’s current
growth rates and the Company’s present and future cash flow position. A variety of factors could cause actual events and results,
as well as the Company’s expectations, to differ materially from those expressed in or contemplated by the forward-looking statements.
Risk factors affecting the Company are discussed in detail in the Company’s filings with the Securities and Exchange Commission.
The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information,
future events or otherwise, except to the extent required by applicable securities laws.
Item
7.01 Regulation FD Disclosure.
Effective
August 18, 2021, executives of Pressure BioSciences, Inc. (the “Company”) have begun using the materials included in Exhibit
99.1 to this report (the “Investor Presentation”) in connection with presentations to existing stockholders of the Company,
potential investors of the Company, and the investment community. The Investor Presentation provides an overview of the Company’s
strategy, performance and future objectives.
The
information provided under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is “furnished” and
shall not be deemed “filed” with the Securities and Exchange Commission or incorporated by reference in any filing under
the Securities Exchange Act or 1934 or the Securities Act of 1933.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Dated:
August 20, 2021
|
PRESSURE
BIOSCIENCES, INC.
|
|
|
|
By:
|
/s/
Richard T. Schumacher
|
|
|
Richard
T. Schumacher,
|
|
|
President
and Chief Executive Officer
|
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024